Hackers claimed they stole Novo Nordisk AI models and manufacturing recipes, escalating cyber risk around drug development and production know-how. The group’s claim describes attempted extortion around sensitive proprietary assets that can impact both R&D workflows and manufacturing execution. Novo has not publicly confirmed the breach details in the provided reporting, but the allegations come amid heightened scrutiny of healthcare data security. If substantiated, incidents like this can drive tighter controls on model provenance, recipe governance, and incident response readiness across pharma AI stacks.